MedPath
HSA Approval

DICYNONE INJECTION 250 mg/2 ml

SIN00279P

DICYNONE INJECTION 250 mg/2 ml

DICYNONE INJECTION 250 mg/2 ml

April 21, 1988

PHARMA TO MARKET PTE. LTD.

PHARMA TO MARKET PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMA TO MARKET PTE. LTD.
Licence HolderPHARMA TO MARKET PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION

**DOSAGE AND ADMINISTRATION** Usual dosages: - Adults: - emergency: 2 to 3 ampoules 3 times daily - pre-operative period, 1 hour before surgery: 2 ampoules - peri-operative period: according to requirement - post-operative period: 1 ampoule, twice daily - In newborn and children: half the adult dose IV or IM ROUTE. The Injectable solution may also be used by the oral route (diluted in a half-glass water) or locally (dabbing).

INTRAVENOUS, INTRAMUSCULAR

Medical Information

**INDICATIONS** In general medicine: - blood loss through fragile capillaries - menorrhagia (heavy periods) with no detectable organic cause - in general or specialized surgery (ENT, ophthalmology, gynaecology): reduction of blood loss during operations, particularly diffuse haemorrhage, patients treated with anticoagulants.

**CONTRAINDICATIONS** - Acute porphyria - Bronchial asthma, confirmed hypersensitivity to sulphites - Hypersensitivity to any of the ingredients of the medicinal product

B02BX01

etamsylate

Manufacturer Information

PHARMA TO MARKET PTE. LTD.

SANOFI WINTHROP INDUSTRIE

Active Ingredients

ETAMSYLATE

250 mg/2 ml

Etamsylate

Documents

Package Inserts

Dicynone_PI.pdf

Approved: October 29, 2014

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DICYNONE INJECTION 250 mg/2 ml - HSA Approval | MedPath